Congressional committee investigates former NCI Director Richard Klausner’s role in $40 million Harvard contract; NIH begins internal review. Klausner: investigation casts “strange innuendoes.” Text of committee’s letter.
Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review.
NCI program announcement available, contract awards listed.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Trump targets HHS in $810M appropriations clawback
- Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?









